Characterization of High-Fat, Diet-Induced, Non-alcoholic Steatohepatitis with Fibrosis in Rats by Xu, Zheng-Jie et al.
ORIGINAL ARTICLE
Characterization of High-Fat, Diet-Induced, Non-alcoholic
Steatohepatitis with Fibrosis in Rats
Zheng-Jie Xu Æ Jian-Gao Fan Æ Xiao-Dong Ding Æ
Liang Qiao Æ Guo-Liang Wang
Received: 8 November 2008/Accepted: 12 April 2009/Published online: 21 May 2009
 Springer Science+Business Media, LLC 2009
Abstract An ideal animal model is necessary for a clear
understanding of the etiology, pathogenesis, and mecha-
nisms of human non-alcoholic steatohepatitis (NASH) and
for facilitating the design of effective therapy for this
condition. We aimed to establish a rat model of NASH
with ﬁbrosis by using a high-fat diet (HFD). Male Spra-
gue–Dawley (SD) rats were fed a HFD consisting of 88 g
normal diet, 10 g lard oil, and 2 g cholesterol. Control rats
were fed normal diet. Rats were killed at 4, 8, 12, 16, 24,
36, and 48 weeks after HFD exposure. Body weight, liver
weight, and epididymal fat weight were measured. Serum
levels of fasting glucose, triglyceride, cholesterol, alanine
aminotransferase (ALT), free fatty acids (FFA), insulin,
and tumor necrosis factor-alpha (TNF-a) were determined.
Hepatic histology was examined by H&E stain. Hepatic
ﬁbrosis was assessed by VG stain and immunohistochem-
ical staining for transforming growth factor beta 1 (TGF-
b1), and alpha-smooth-muscle actin (a-SMA). The liver
weight and liver index increased from week 4, when
hepatic steatosis was also observed. By week 8, the body
weight and epididymal fat weight started increasing, which
was associated with increased serum levels of FFA, cho-
lesterol, and TNF-a, as well as development of simple fatty
liver. The serum ALT level increased from week 12. Ste-
atohepatitis occurred from weeks 12 through 48. Apparent
hepatic perisinosodial ﬁbrosis did not occur until week 24,
and progressed from week 36 to 48 with insulin resistance.
Therefore, this novel model may be potentially useful in
NASH study.
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Introduction
Non-alcoholic steatohepatitis (NASH) is part of the spec-
trum of non-alcoholic fatty liver disease (NAFLD), cur-
rently the most common form of chronic liver disease in the
United States and in many parts of the world [1–4]. NAFLD
is a continuum of diseases characterized by macrovesicular
hepatic fat accumulation alone (simple hepatic steatosis) or
accompanied by signs of hepatocyte injury, mixed inﬂam-
matory cell inﬁltrate, and variable hepatic ﬁbrosis in peri-
cellular distribution (NASH); NASH may lead to cirrhosis
and hepatocellular carcinoma (HCC) [4–6]. There is strong
evidence that the prevalence of NAFLD worldwide has
increased substantially over the past decades in parallel with
global trends in over-nutrition (decreased physical activity
with disproportionate high-fat food intake), obesity, type 2
diabetes mellitus (T2DM), and the metabolic syndrome
(MetS) [1–4]. Present trends in the obesity and diabetes
pandemic indicate that a further increase in NAFLD prev-
alence is likely in the near future [1].
However, very few effective therapeutic approaches for
full-blown NAFLD/NASH are available up until this stage
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DOI 10.1007/s10620-009-0815-3[5, 6]. Development of efﬁcient prevention and therapeutic
options for NASH is hampered by a clear understanding of
the etiology and mechanisms of this condition, which in
turn is limited by a lack of a suitable study model [7, 8]. An
animal model of NASH constitutes a very important
approach to understanding the molecular mechanisms of
NASH [9–11]. An in vivo NASH model in animals is also a
very important method to test the therapeutic potency of
certain agents against NASH [12–14]. NASH in animals
can be produced by a wide variety of factors leading to
changes in hepatic fat disposition. Some of these factors
include over-nutrition, methionine and choline deﬁcient
(MCD) diet, physical inactivity, insulin resistance (IR),
hepatotoxins, and deﬁciency of leptin and/or its receptors
[15–30]. However, the currently available animal models
of NASH are associated with various drawbacks in that
they do not or only partially reﬂect the real pictures of
human NASH in terms of etiology, pathogenesis, and
disease mechanisms [8–11]. For example, spontaneous
transition to signiﬁcant steatohepatitis does not occur in
nutritional and metabolic models of steatosis [8, 9].
Although a MCD diet induces typical changes of NASH in
rodents [16, 17], and a 3-week ad libitum administration of
a liquid high-fat diet (LHFD) also produces the typical
pathology of NASH, including steatosis, hepatic inﬂam-
mation, and ﬁbrosis in Sprague–Dawley rats [31], these
nutritional models do not reﬂect the diet features seen in
NASH patients, as MCD is not commonly seen in human
beings, and the MCD model can cause severe weight loss
and cachexia, which are not characteristic of NASH seen in
patients [11, 16, 17]. In addition to a lack of progressive
pathology seen in typical NASH, the fatty acid composition
of the LHFD model is vastly different from that of the diet
of NASH patients in which a higher level of saturated fatty
acid (SFA) and a low level of polyunsaturated fatty acid
(PUFA) are typical [18, 19]. The genetic rodent models of
NASH also have limitations [7, 9, 29, 30]. For example,
NASH models induced by deﬁciency of leptin and its
receptors, although useful in assessing the biological sig-
niﬁcance of the gene involved, do not reﬂect the natural
etiological background of NAFLD/NASH in patients and
are thought to be resistant to the development of ﬁbrosis.
Pharmacological models of NASH are also frequently
used, but they have a major limitation in not reﬂecting the
obesity and IR, which are critically important in the
development of human NASH. Obviously, all these models
do not reﬂect the multi-factorial features of NASH
observed in patients and thus are ‘‘non-physiological.’’
Consequently, there is an outstanding need to establish
NASH models that can best mimic the real pathogenesis
and etiology of human NASH [8, 9].
In this study, we aimed to create a novel rat model of
NASH by feeding the animals with a home-made high-fat
diet (HFD), with the hope to reproduce the key features of
human NASH for future research.
Methods
Animals and High-Fat Diet
Sprague–Dawley rats were purchased from Shanghai
Experimental Animal Center of Chinese Academy of Sci-
ences (Shanghai, China) and bred in an experimental ani-
mal unit of Shanghai First People’s Hospital. All animals
were allowed to acclimatize for a week on the normal diet
before grouping. One hundred eighteen male rats weighing
140–160 g were then randomly divided into two groups:
the HFD-fed group (n = 77) and control (pair-fed, PF)
group (n = 41). The HFD group was prepared by mixing
2 g cholesterol and 10 g lard oil with 88 g normal pellet
chow. The HFD was composed of the following energy
sources: 52% was provided by carbohydrates, 30% by fat,
and 18% by protein (overall calories: 4.8 kcal/g). The PF
rats were fed normal rat pellet chow, which contains 67%
carbohydrates, 10% fat, and 23% protein as the energy
sources (overall calorie: 3.6 kcal/g). The composition of
the diet used in this study and comparison with the MCD
diet are summarized in Table 1. All rats were given
humane care in a temperature-controlled environment with
a 12:12-h light-dark cycle. They were housed in plastic
cages in groups of four and were permitted ad libitum
consumption of water and diet. The care and use of animals
in this study was under the guidelines approved by the
Animal Ethics Committee of the Shanghai Jiao-Tong
University School of Medicine.
Experimental Procedures
All rats of both HFD-fed and PF groups were maintained at
the above-mentioned conditions for 4–48 weeks. At the
end of the time points (4, 8, 12, 16, 24, 36, and 48 weeks
after feeding with appropriate diet), animals were fasted
Table 1 Major components of the HFD and comparison with PFD
and MCD diet (g/100 g diet)
PFD HFD MCD diet
Carbohydrates 60 52.8 65.5
Cholesterol 0 2.0 0
Fat 4 13.5 10
Protein 20 17.6 17.5
Methionine 0.78 0.69 0
Choline 0.125 0.11 0
HFD high-fat diet, PFD pair-fed diet, MCD methionine and choline
deﬁciency
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123overnight and then killed by exsanguinations under light
pentobarbital. The body weight was recorded. The blood
samples were collected from the abdominal aorta and
maintained at -20C until assayed. Liver was quickly
removed and weighed. Part of the liver tissues was snap
frozen in liquid nitrogen for RNA and protein analysis. A
small piece of liver was immediately ﬁxed in 10% neutral-
buffered formalin for further histology analysis. The epi-
didymal fat was removed and measured, and used as an
indicator for visceral adipose tissue.
Serum Biochemistry and Tumor Necrosis Factor-Alpha
(TNF-a)
Serum levels of fasting glucose, triglyceride, total choles-
terol (TC), and alanine aminotransferase (ALT) were
measured by a multichannel automatic analyzer (Bayer
Advia 1650, Germany). Serum levels of free fatty acids
(FFA) were assayed using a commercial kit (Wako Pure
Chemical Industries, Ltd., Japan). Serum insulin levels
were detected (only at week 12, 24, 36, and 48) by a
radioimmunoassay-based commercial kit. TNF-a levels
were measured by an ELISA-based commercial kit (End-
ogen, Inc., USA).
Hepatic Pathological Evaluation
For light microscopic analysis of liver histology, the par-
afﬁn-embedded liver tissues were cut into 4-lm sections,
and standard hematoxylin-eosin (H&E) staining was per-
formed. Hepatic ﬁbrosis was assessed by Masson stain. Ten
2009 light microscopic ﬁelds were viewed on each section
and scored for the severity of hepatic steatosis, inﬂamma-
tion and ﬁbrosis according to the following criteria [32]:
For hepatic steatosis: grade 0, no fat; grade 1, steatosis
occupying less than 33% of the hepatic parenchyma; grade
2, 34–66% of the hepatic parenchyma; grade 3, more than
66% of the hepatic parenchyma; for inﬂammatory cell
inﬁltration: grade 0: none; grade 1, 1–2 foci/ﬁeld; grade 2,
3–4 foci/ﬁeld; grade 3, more than 4 foci/ﬁeld. The staging
of hepatic ﬁbrosis was investigated by Masson staining as
follows: 0, none; 1, mild, zone 3, perisinusoidal; 2, mod-
erate, zone 3, perisinusoidal; 3, portal/periportal; 4, bridg-
ing ﬁbrosis [32].
Mitochondria of the liver were assessed by transmission
electron microscopy (TEM), which as performed by the
Electron Microscopy Center of the Shanghai Jiao Tong
University School of Medicine.
Immunostaining of a-SMA and TGF-b1
Parafﬁn-embedded liver tissues were deparafﬁnized with
xylene series, washed well with graded ethanol and
permeabilized with 0.2% trypsin at room temperature for
30 min. After inactivation of endogenous peroxidase by
3% H2O2 for 20 min, tissue sections were washed with
phosphate-buffered saline (PBS) and reacted with appro-
priate primary antibodies at 4C overnight. Rabbit anti-rat
transforming growth factor-beta 1 (TGF-b1) (Santa-Cruz
Biotechnology Inc., Santa Cruz, CA) was diluted 100-fold
in PBS. Mouse anti-rat alpha-smooth-muscle actin (a-SMA)
(Sigma, Ltd., St Louis, MO) was diluted 200-fold in PBS.
Negative control was included in each reaction with pri-
mary antibodies being replaced by PBS. Following primary
antibody incubation, the tissue sections were washed in
PBS and incubated with two-step appropriate secondary
antibodies (anti-rabbit or anti-mouse, Antibody Diagnos-
tica Inc., USA) for 30 min at room temperature. The tissue
sections were then washed with PBS, reacted with 0.01%
H2O2 and 3,3’ diaminobenzidine (DAB; Dako, Denmark)
at room temperature for 3–5 min, washed again with PBS
and covered with glycerin gelatin for light microscopy. The
immunostaining results were evaluated by an experienced
hepatopathologists (XZJ) in at least ﬁve microscopic ﬁelds
(9200) of each section.
Statistical Analysis
Data were expressed as mean ± SD unless otherwise
speciﬁed. The Student’s t test was used to analyze indi-
vidual differences. Rank samples were analyzed by the
rank-sum test. Rate comparison was analyzed by the U test.
A value of P\0.05 was considered to be statistically
signiﬁcant.
Results
Effects of HFD on Body Weight, Visceral Obesity, and
Liver Index
No rat died in either group during the whole experimental
period. Body weight increased steadily from week 4 of
both groups, but more signiﬁcantly and progressively so in
HFD-fed rats after week 16. Development of visceral
obesity, as indicated by a progressive increase in epididy-
mal fat weight, started as early as 4 weeks after HFD
feeding. Along with the increased body weight and visceral
adiposity, there was a marked increase in liver weight of
HFD rats starting from week 4, leading to a progressively
increased liver index (LI, calculated as liver weight/body
weight 9 100%). The increase in liver weight, epididymal
fat weight and LI was more signiﬁcant in HFD-fed rats.
These results are summarized in Table 2.
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123Serum Lipids, ALT, FFA, and TNF-a
The serum concentration of TC increased signiﬁcantly
from week 12 and continued to increase thereafter in HFD-
fed rats. The serum concentration of triglycerides varied
during the study course, and no signiﬁcant difference
between the two groups was observed. Compared with PF-
fed controls, the serum ALT concentration increased from
week 12 to week 48, and peaked at week 16 in HFD rats.
Relative to PF-fed rats, the serum concentration of FFA
increased progressively from week 4 through week 48 in
HFD-fed rats, which is associated with a signiﬁcant and
progressive increase in the serum TNF-a, which peaked
between weeks 12 and 16. The serum glucose levels did not
increase until week 36. The above results are summarized
in Table 3.
HOMA-IR Index
The HOMA-IR index of each group was calculated as
follows: (fasting serum glucose 9 fasting serum insulin)/
22.5. At both 12 and 24 week, the IR index was similar in
the two groups. From week 36 to week 48, the IR index
increased signiﬁcantly in HFD-fed rats (Table 4).
Hepatic Steatosis and Inﬂammation
Overall, no abnormalities were observed in the liver tissues
of the PF-fed control rats both macroscopically and
microscopically. In contrast, livers from HFD-fed rats were
generally enlarged with a yellowish and greasy appearance
and a crisp texture.
Under the light microscope, livers of HFD-fed rats at
week 4 showed diffusely mixed hepatic steatosis, which
was predominantly microvesicular and mainly involved
zone 3 hepatocytes (Fig. 1). Steatosis advanced to a more
severe degree after 8 weeks of HFD feeding. At this time
point, 11 out of 12 rats developed grade 1 or 2 hepatic
steatosis, and mild hepatic lobular inﬂammation was
present (Fig. 1).
After 12 weeks of HFD feeding, all rats developed
hepatic changes consistent with moderate to severe steta-
osis. Hepatic inﬂammation was more severe than those in
HFD-fed rats at weeks 4 and 8 (Table 5). All liver samples
showed moderate to severe lobular inﬂammation and focal
necrosis. Both acute and chronic hepatic inﬂammation was
present (as demonstrated by inﬁltration with polymorphs
and mononuclear cells, respectively). However, only mild
inﬂammation was observed in the portal zone at this stage
(Fig. 1).
An even greater degree of hepatic steatosis and lobular
inﬂammation was observed by week 16 (Table 5). Apart
from inﬁltration with numerous polymorphs and mononu-
clear cells in hepatic lobules, intervening necrotic foci were
frequently observed. Portal inﬂammation was also noted
(Fig. 1).
From week 24 to week 48, moderate to severe hepatic
steatosis in HFD-fed rats was still present, but the lobular
and portal inﬂammation was similar to that of the week 12
and week 16 groups (Table 5; Fig 1).
Hepatic Fibrosis
Hepatic ﬁbrosis was assessed by Masson stain, immuno-
staining a-SMA and TGF-b1 in the harvested liver tissues.
No histological signs of hepatic ﬁbrosis were observed in
PF-fed controls rats. By Masson stain, obvious hepatic
ﬁbrosis was not observed at weeks 4, 8, and 12 in HFD-fed
rats. At week 16, mild perisinusodial ﬁbrosis was noted in
four rats. At week 24, all rats developed preisinusoidal
ﬁbrosis in zone 3. Perivenular and periportal ﬁbrosis also
was present (Table 5). At weeks 36 and 48, the hepatic
ﬁbrosis was more severe. Bridging ﬁbrosis was observed in
Table 2 Body weight, epididymal fat weight, and liver indexes
Week n Body weight (g) Epididymal fat (g) Liver index (%)
PFD HFD PFD HFD PFD HFD PFD HFD
4 6 12 329.2 ± 12.7 332.9 ± 26.6 8.5 ± 1.5 9.7 ± 1.5 2.5 ± 0.1 3.1 ± 0.1*
8 6 12 439.2 ± 33.1 435.8 ± 26.7 10.3 ± 1.2 12 ± 1.2** 2.8 ± 0.1 3.4 ± 0.5**
12 6 12 450.8 ± 50.6 458.8 ± 28.3 12.1 ± 2.3 14.5 ± 2.0* 2.1 ± 0.2 3.5 ± 0.2**
16 6 12 478.2 ± 36.8 505.8 ± 60.1 14.0 ± 1.8 17.4 ± 0.7** 2.3 ± 0.3 3.9 ± 0.5**
24 5 9 493.3 ± 51.1 549.9 ± 50.0* 14.8 ± 2.3 19.9 ± 2.1** 2.3 ± 0.3 4.0 ± 0.1**
36 6 10 506.3 ± 47.2 575.4 ± 45.5* 15.4 ± 2.4 21.3 ± 4.4** 2.2 ± 0.2 4.2 ± 0.3**
48 6 10 511.4 ± 56.8 591.94 ± 76.7* 15.6 ± 2.7 24.4 ± 7.4** 2.2 ± 0.3 4.4 ± 0.5**
Liver index calculated as liver weight/body weight 9 100%
HFD high-fat diet, PFD pair-fed diet
* P\0.05 vs. PF, ** P\0.01 vs. PF
934 Dig Dis Sci (2010) 55:931–940
123some rats. The representative staining results of week 24,
36, and 48 livers are shown in Fig. 2.
In the PF-fed control livers, a-SMA, and TGF-b1 were
localized along the blood vessels and occasionally on the
sinusoidal walls. In the livers of week 4 and 8 HFD-fed
rats, weak a-SMA staining was observed on the sinusoidal
wall, but the hepatic expression of TGF-b1 was similar to
that of the PF-fed control rats. From weeks 12 through 48,
progressively increased expression of a-SMA and TGF-b1
were observed. Cells stained positive for a-SMA were
largely localized along the sinusoidal wall, in inﬂammatory
cells and in the areas with remarkable perisinusoidal
ﬁbrosis. Positive staining of TGF-b1 had similar histo-
logical distribution, except it was occasionally observed in
hepatocytes (Fig. 3).
Changes of Mitochondria
At the ultrastructural level, electron microscopy was
performed to assess the changes of mitochondria.
Degenerative changes, including swelling, rounding up
and loss of cristae were observed in the livers of HFD-
fed rats. Impairment of mitochondria became increas-
ingly severe as the rats were exposed to HFD for a
longer period of time. Stacks of intramitochondrial para-
crystalline inclusion bodies were noted in some mito-
chondria (Fig. 4).
Discussion
Medical research is often constrained by the limited
availability of both healthy and diseased tissue, making
animal models an essential tool for studies of disease
pathogenesis. Ideally, animal models should not only
reproduce the established pathological expression of the
human disease, but also recapitulate the context within
which a disease develops and progress [11]. These issues
are pertinent to hepatology research, in particular the study
of NASH and its consequences. To date, there is no single
animal model that displays the range of histopathologic
and pathophysiologic features associated with NASH [7–9,
31]. Currently available models either mimic the histo-
pathologic features of NASH or the pathogenic correlates
of human NASH. The majority of animal models with IR
are defective in leptin or adiponectin signaling and do not
develop steatohepatitis spontaneously with the signiﬁcant
levels of ﬁbrosis seen in patients. Animal models of ﬁ-
brosing steatohepatitis usually are under high levels of
oxidant stress as a result of increased hepatic fat load in the
setting of reduced levels of antioxidants, resulting in
lipotoxicity. These models usually do not exhibit
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123peripheral IR and have other limitations, such as excessive
weight loss, usually not seen in the human disorder [8, 9,
11, 31]. Therefore, a practically simple model that can best
mimic the clinical aspects of NASH is very necessary. In
this study, we produced a HFD by adding 10% (w/w) lard
oil and 2% (w/w) cholesterol to the normal pellet chow.
Following 48 weeks of exposure, all experimental rats
developed hepatic changes typical of human NASH. Based
on several aspects described below, we considered our
model a practical and accurate one for studying NASH.
In our model, NAFLD/NASH was successfully repro-
duced in all rats chronically fed with HFD. Grade 1 hepatic
steatosis (i.e., steatosis of less than 33% of the hepatic
parenchyma) was observed at week 4, and fatty liver
(steatosis of more than 33% of the hepatic parenchyma)
developed by week 8. By week 12 through week 48, ste-
atohepatitis developed, and abnormal liver function
occurred.
As development of hepatic ﬁbrosis is one of the clinical
features of late stage NAFLD (type 4), we investigated
whether ﬁbrosis occurred in our model. Masson stain
revealed that a small percentage of rats developed mild
perisinosodial ﬁbrosis by week 16. At week 24, all the rats
developed perisinosodial ﬁbrosis. At week 36 and 48, the
Fig. 1 H&E stain of liver tissues from control (a), HFD-fed livers at weeks 8 (b), 16 (c), 24 (d), 36 (e), and 48 (f). Original magniﬁcations:
9100 (a–d), 9200 (e, f)
Table 4 Serum glucose, insulin, and IR index
Week Glucose (mmol/l) Insulin (pmol/l) IR index
PFD HFD PFD HFD PFD HFD
12 5.2 ± 1.5 5.4 ± 1.8 98.03 ± 14.07 96.40 ± 12.90 23.72 ± 6.99 23.34 ± 7.61
24 5.4 ± 1.8 5.6 ± 2.0 103.58 ± 18.10 95.11 ± 27.78 25.21 ± 9.19 24.87 ± 9.48
36 6.2 ± 1.7 10.1 ± 1.6* 97.34 ± 16.35 107.95 ± 22.24 27.38 ± 8.62 48.07 ± 11.02*
48 6.4 ± 1.9 10.5 ± 2.6* 94.46 ± 18.22 99.98 ± 23.09 27.41 ± 8.17 45.49 ± 11.36*
HOMA-IR index = (glucosue 9 insulin)/22.5
In PF groups at weeks 4, 8, 12, and 16, n = 6; at week 24, n = 5
In HFD groups at weeks 4, 8, 12, and 16, n = 12; at week 24, n = 9
HFD high-fat diet, PFD pair-fed diet
* P\0.05 vs. PFD
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123hepatic ﬁbrosis was more severe. Bridging ﬁbrosis was
observed in some rats. The observed sequence of events
(simple fatty liver, steatohepatitis, and steatohepatitis with
progressive ﬁbrosis) in our experimental rats closely
mimics that of human spectrum of NASH. Further, these
pathological features were predominant in zone 3. The
lobular inﬂammation was more severe than portal inﬂam-
mation. At the early stage, ﬁbrosis had more of a
Table 5 Scores of hepatic steatosis, inﬂammation, and ﬁbrosis staging
Group Week n Steatosis score Inﬂammation score Fibrosis stage (n)
0 1234
PFD 41 0 0 29 0 0 0 0
HFD 4 12 1.67 ± 0.79* 0 12 0 0 0 0
8 12 2.33 ± 0.65* 0.3 ± 0.24 12 0 0 0 0
12 12 2.75 ± 0.45* 1.70 ± 0.77*
,a 1 20000
16 12 2.91 ± 0.29* 2.57 ± 0.71*
,b 84000
24 9 2.67 ± 0.50* 1.82 ± 0.60*
,c 03321
36 10 2.71 ± 0.61* 1.93 ± 0.73*
,c 02422
48 10 2.65 ± 0.58* 1.91 ± 0.69*
,c 01432
In PFD groups at weeks 4, 8, 12, and 16, n = 6; at week 24, n = 5
In HFD groups at weeks 4, 8, 12, and 16, n = 12; at week 24, n = 9
HFD high-fat diet, PFD pair-fed diet
* P\0.05 vs. PFD group
a P\0.05 vs. weeks 4 and 8 HFD group
b P\0.05 vs. week 12 HFD group
c P\0.05 vs. week 16 HFD group
Fig. 2 Masson stain was
performed to detect ﬁbrosis of
liver tissues from control (a)
and HFD-fed liver at week 24
(b), 36 (c), and 48 (d). Original
magniﬁcations: 9200
Dig Dis Sci (2010) 55:931–940 937
123perisinosodial pattern. The fact that the severity of hepatic
steatosis and inﬂammation was not compatible with that of
ﬁbrosis suggests that the observed pathological changes
closely mimic the pathological changes observed in human
‘‘cryptogenic cirrhosis’’ [4, 6]. Another pathological fea-
ture reproduced by this model is the presence of mito-
chondrial lesions such as swelling, rounding up and loss of
crista. These changes are frequently observed in human
NASH and are thought to be mechanistically linked to this
condition [7, 8, 28, 33].
NAFLD/NASH is now considered one of the hepatic
manifestations of MetS [1–5], which should ideally be
reﬂected in animal models of NASH. In particular,
increased serum levels of FFA and TNF-a are believed to
be the two key factors in the pathogenesis of IR and MetS
[3, 6]. In our model, HFD-fed rats developed NAFLD,
visceral obesity and hyperlipidaemia after 24 weeks of
exposure. In addition, these rats also exhibited increased
serum levels of FFA and TNF-a by week 24. These
changes are mechanistically linked to the development of
Fig. 3 Effect of HFD on hepatic expression of TGF-b1 and a-SMA.
Immunostaining was performed as described in ‘‘Materials and
Methods;’’ positively stained cells were counted in ﬁve randomly
chosen high-power ﬁelds (HPF) and expressed as the average number
of positive stain cells per HPF. *P\0.05, vs. control, week 4 and
week 8 of respective groups. The representative results are shown
Fig. 4 Electron microscopy of
hepatic mitochondria in control
(a), week 12 (b), week 16 (c),
and week 24 (d) of HFD groups.
Magniﬁcations: a, b: 916,800;
c: 99,600; d: 97,600
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123IR and MetS [7–9]. Conventional concepts hold that vis-
ceral obesity and IR, mostly mediated by adipokines such
as TNF-a, result in increased FFA release from visceral
adipose tissue with the consequent enhancement of lipid
delivery to the liver. Furthermore, FFA can stimulate
TNF-a expression in hepatocytes and in adipocytes, and
thus is closely implicated in the etiology of IR [7, 34].
From week 36 to week 48, HFD-fed rats developed
hyperglycemia and increased IR index. The appearance of
these phenomena was later than that of NAFLD and vis-
ceral obesity. We think our current model mimics the real
process of human MetS. According to the well-known
‘‘single gateway hypothesis,’’ hepatic steatosis and hepatic
IR are early events that usually precede pancreas insulin
secretion decompensation and hyperglycemia [34]. The
connection between NASH and hyperglycemia is indicated
by the epidemiological ﬁnding of others that NAFLD sig-
niﬁcantly increases the risk of T2DM and cardiovascular
complications, thus making NAFLD a pro-diabetic/pro-
atherogenic state [3, 5, 34, 35]. Therefore, we believe that
the HFD in our study induces changes of NASH that mimic
almost all clinical aspects of human NASH, depending on
the experimental design.
In conclusion, we created a practically simple but
accurate rat NASH model. It reproduced the pathological
sequence of events typical of human NASH. This model
also displays some of the features of MetS, such as
increased visceral obesity, hyperlipidemia, increased FFA,
and TNF-a. The HFD can be easily home-made with good
safety and low cost. Thus, our model may serve as an ideal
tool to study the pathogenesis of NASH. However, further
animal studies are warranted before this model can be
widely promoted in NASH study.
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